Microcap Cognition Therapeutics (NASDAQ:CGTX) has skyrocketed 35% in Thursday trading after stating the company had a ...

The arrival of agentic AI at Goldman Sachs, in which programs don’t just help with tasks but execute complex jobs, signals a ...

Goldman Sachs seems to be the only major bank implementing a start-to-finish AI-coding tool like Devin, but its competitors ...

A new longitudinal study suggests that overall well-being—and especially a strong sense of purpose—are important components ...

For decades, the story of Alzheimer’s research has been dominated by a battle between amyloid-beta and tau amyloids, both of which can kill neurons and impact the brain’s abil ...

Cognition Therapeutics shares surged after the clinical-stage company said it completed the end-of-Phase 2 meeting with the Food and Drug Administration for its zervimesine drug. Shares were up 30% at ...

Cognition Therapeutics Inc. (NASDAQ:CGTX) saw its stock climb sharply by 75% following a productive end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) concerning its Alzheimer’s ...

The AI software engineer making its debut on Wall Street was created by Cognition, a startup founded in 2023 and backed by ...

Turning a childhood curiosity into cutting-edge research, Richmond explores animal behavior and cognition in natural ...

To better understand human cognition, scientists trained a large language model on 10 million psychology experiment questions ...

Goldman Sachs ' fondness for technology expands with their latest testing of "Devin," the AI coding agent from Cognition which went viral last year because of its capabilities as well as its ...

Positive Discussion on Path Forward for Registrational ProgramPURCHASE, N.Y., July 10, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical ...